Compugen Ltd (NAS:CGEN)
$ 1.57 -0.06 (-3.68%) Market Cap: 141.45 Mil Enterprise Value: 31.69 Mil PE Ratio: 52.62 PB Ratio: 2.33 GF Score: 53/100

Compugen Ltd at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript

Sep 22, 2020 / 01:10PM GMT
Release Date Price: $17.65 (-0.45%)
Mark Alan Breidenbach
Oppenheimer & Co. Inc., Research Division - Executive Director & Senior Analyst

All right. So it's 9:10. Let's go ahead and get started with day 2 of the Oppenheimer Fall Healthcare and MedTech Summit (sic) [Fall Healthcare Life Sciences & MedTech Summit]. My name is Mark Breidenbach. And I'm pleased to introduce our next presenting company, Compugen Ltd., based out of Holon, Israel and South San Francisco, California.

Joining us this morning to walk us through the story, we have Compugen's CEO, Anat Cohen-Dayag. And for those new to the story, Compugen is a clinical stage therapeutics company focused on drugging novel immune checkpoints with applications in oncology and autoimmune disease.

The company's lead program, COM701, has demonstrated monotherapy activity in a Phase I dose escalation trial and is currently being evaluated in expansion cohorts focusing on specific tumor types. COM701 also recently entered into an all-comers triple combination trial with Bristol-Myers Squibb's TIGIT antibody and PD-1 checkpoint antibody. As Anat will explain,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot